Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000524757 | SCV000626668 | uncertain significance | Glycogen storage disease type III | 2022-10-17 | criteria provided, single submitter | clinical testing | This sequence change replaces leucine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 409 of the AGL protein (p.Leu409Arg). This variant is present in population databases (rs200459772, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with AGL-related conditions. ClinVar contains an entry for this variant (Variation ID: 456451). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt AGL protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Gene |
RCV001755796 | SCV001986582 | uncertain significance | not provided | 2020-06-09 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Genome- |
RCV000524757 | SCV002055096 | uncertain significance | Glycogen storage disease type III | 2021-07-15 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV001755796 | SCV004227871 | uncertain significance | not provided | 2023-03-27 | criteria provided, single submitter | clinical testing | PP3 |
Natera, |
RCV000524757 | SCV002091480 | uncertain significance | Glycogen storage disease type III | 2019-10-28 | no assertion criteria provided | clinical testing |